Cargando…
Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
PURPOSE: Ceftazidime–avibactam is a novel β-lactam/β-lactamase inhibitor combination recently approved in Europe and the USA for the treatment of adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), among other indications. In the phase III REPROVE trial (NCT01808...
Autores principales: | Das, Shampa, Zhou, Diansong, Nichols, Wright W., Townsend, Andy, Newell, Paul, Li, Jianguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223046/ https://www.ncbi.nlm.nih.gov/pubmed/31836928 http://dx.doi.org/10.1007/s00228-019-02804-z |
Ejemplares similares
-
Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers
por: Dimelow, Richard, et al.
Publicado: (2018) -
Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
por: Li, Jianguo, et al.
Publicado: (2018) -
Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
por: Das, Shampa, et al.
Publicado: (2015) -
Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)